ArticleNPJ genomic medicine2021
Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer.
Article in NPJ genomic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response.International journal of molecular sciences · 2025Pooled it
- Urinary extracellular vesicle microRNA profiles and prostate cancer biopsy outcome: Moderate discrimination and quantified optimism under leakage-controlled machine learning.Biochemistry and biophysics reports · 2026Article
- Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).International journal of oncology · 2026Review
- Prostate Cancer Biomarkers with a Focus on Galectin-3: Emerging Clinical and Therapeutic Implications.Current oncology (Toronto, Ont.) · 2026Review
- Epigenetic and Liquid Biopsy Biomarkers in Prostate Cancer: Bridging Tumor Heterogeneity and Clinical Implementation.Cancers · 2026Review
- Urinary miR-191-5p levels are significantly reduced after radical prostatectomy in patients with prostate cancer.Cancer cell international · 2026Article
- MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring.Cells · 2026Review
- Nanorobots and Exosomes: Driving the New Frontier for Bladder Tumors through Non-Coding RNAs.Oncology research · 2026Review
- The dual roles of exosomes in prostate cancer: mechanisms in tumorigenesis and avenues for clinical translation.Frontiers in immunology · 2026Review
- Effects of miR-451 on the proliferation, invasion and migration of papillary thyroid cancer cell line TPC-1 by regulating the PI3K/AKT/mTOR signaling pathway.Endocrine connections · 2026Article
- Liquid biopsy in genitourinary cancers: Diagnostic and prognostic implications.World journal of clinical oncology · 2025Review
- Exosomal microRNAs as prostate cancer biomarkers and treatments: recent progress.Medical oncology (Northwood, London, England) · 2025Review
- Two-dimensional analysis of plasma-derived extracellular vesicles to determine the HER2 status in breast cancer patients.Breast cancer research : BCR · 2025Article
- Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.Discover oncology · 2025Review
- Small extracellular vesicles: crucial mediators for prostate cancer.Journal of nanobiotechnology · 2025Review
- Extracellular vesicles in burn injury: roles, mechanisms, and applications.Burns & trauma · 2025Review
- Relationship between exosomes and cancer: formation, diagnosis, and treatment.International journal of biological sciences · 2025Review
- Exosomal microRNAs: impact on cancer detection, treatment, and monitoring.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Circulating biomarkers for diagnosis and response to therapies in cancer patients.International review of cell and molecular biology · 2025Review
- miR-148b-5p regulates hypercalciuria and calcium-containing nephrolithiasis.Cellular and molecular life sciences : CMLS · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Predicting the risk of metastasis before starting prostate cancer (PCa) treatment can minimize the overtreatment of indolent cases and help choosing appropriate treatment. The levels of circulating microRNAs (miRNAs) from body fluids can be used as noninvasive prognostic biomarkers. In this study, urinary exosomal miRNA expression profiles of 149 PCas were determined and the miRNAs associated with metastasis were identified: miR-21, miR-16, miR-142-3p, miR-451, and miR-636. When evaluating clinical factors together, miR-21, miR-451, miR-636, and preoperative prostate-specific antigen (PSA) level remained significant in the multivariate analysis. Based on them, we developed a "Prostate Cancer Metastasis Risk Scoring (PCa-MRS)" model. The PCa-MRS showed superior stratification power (AUC = 0.925) to preoperative PSA or clinical Gleason score. Patients with high scores showed significantly poorer biochemical recurrence-free survival than those with low scores (P = 6.53 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.